Naason Science
Naason Science
  • Home
  • Research
    • Preclinical Research
    • CNS Models
    • Pain Models
    • Endometriosis Models
    • Oncology Models
    • Ophthalmology Models
    • Orthopedic Models
    • Metabolic Disease Models
    • Psychiatric Models
    • In Vitro
    • Safety & Toxicity Studies
  • News
  • Careers
    • Naason Team
    • Join the team
  • Investors
  • Contact
  • More
    • Home
    • Research
      • Preclinical Research
      • CNS Models
      • Pain Models
      • Endometriosis Models
      • Oncology Models
      • Ophthalmology Models
      • Orthopedic Models
      • Metabolic Disease Models
      • Psychiatric Models
      • In Vitro
      • Safety & Toxicity Studies
    • News
    • Careers
      • Naason Team
      • Join the team
    • Investors
    • Contact
  • Home
  • Research
    • Preclinical Research
    • CNS Models
    • Pain Models
    • Endometriosis Models
    • Oncology Models
    • Ophthalmology Models
    • Orthopedic Models
    • Metabolic Disease Models
    • Psychiatric Models
    • In Vitro
    • Safety & Toxicity Studies
  • News
  • Careers
    • Naason Team
    • Join the team
  • Investors
  • Contact

Investor relations

Naason Science announces split of shares

March 31, 2022


The annual shareholders meeting on March 30, 2022, decided to divide one share of 5,000 won per share into 10 shares of 500 won per share during the annual meeting of shareholders. 


Accordingly, all shareholders should submit the old stock certificates to the headquarters within one month from the date following this announcement date.


Please download the full announcement below.

Naason Stock split announcement_20220331 (pdf)Download

© 2023 Naason Science Inc. All rights reserved.

  • Home
  • Preclinical Research
  • News
  • Areas of Expertise
  • Privacy & Terms
  • Contact

Welcome to Naason Science website!

Our website uses cookies. By continuing to use this site, you accept our use of cookies.

DeclineAccept